Scientist creates new cancer drug that is ten times more potent

August 29, 2012
Lee and his research team used carboranes to create a new cancer drug that is 10 times more potent than current cancer-fighting drugs. Credit: Nathan Hurst/University of Missouri

Legend has it that Ralph Waldo Emerson once said, "Build a better mousetrap, and the world will beat a path to your door." University of Missouri researchers are doing just that, but instead of building mousetraps, the scientists are targeting cancer drugs. In a new study, MU medicinal chemists have taken an existing drug that is being developed for use in fighting certain types of cancer, added a special structure to it, and created a more potent, efficient weapon against cancer.

"Over the past decade, we have seen an increasing interest in using carboranes in drug design," said Mark W. Lee Jr., assistant professor of chemistry in College of Arts and Science. "Carboranes are clusters of three elements—, carbon and hydrogen. Carboranes don't fight cancer directly, but they aid in the ability of a drug to bind more tightly to its target, creating a more potent mechanism for destroying the ."

In the study, Lee and his research team used carboranes to build new drugs designed to shut off a cancer cell's energy production, which is vital for the cell's survival. All cells produce energy through complex, multi-step processes. The key to an effective drug is targeting the process that cancer cells depend on more than healthy cells. By increasing the of a drug, a smaller dose is required, minimizing side effects and increasing the effectiveness of the therapy. With carboranes, Lee found that the drug is able to bind 10 times more powerfully.

The video will load shortly.
Mark W. Lee Jr., an assistant professor of chemistry at the University of Missouri, and his research team have used carboranes to enhance cancer-fighting drugs. They recently created one drug that is 10 times more potent than current cancer-fighting drugs. The technology could be used to address other problems such as migraine headaches or Alzheimer's. Credit: Nathan Hurst/University of Missouri

"The reason why these drugs bind stronger to their target is because carboranes exploit a unique and very strong form of hydrogen bonding, the strongest form of interactions for drugs," Lee said.

Lee said that this discovery also will lead to further uses for the drug.

"Too often, after radiation or , cancer cells repair themselves and reinvade the body," Lee said. "This drug not only selectively shuts off the for the cancer cells, but it also inhibits the processes that allow those cancer cells to repair themselves. When we tested our carborane-based drugs, we found that they were unimaginably potent. So far, we have tested this on breast, lung and colon cancer, all with exceptional results."

According to Lee, this is the first study to show systematically how carboranes can improve the activity of a drug. Lee believes this discovery will open additional possibilities of improving drugs that are used to treat other diseases, not just cancer.

"The end result is that these could be many thousands of times more potent than the drugs that are used in the clinics today," Lee said.

While it will be several years before the new drug would be available on the market, Lee said that clinical trials could begin within the next two years. Additionally, further testing on other is underway. The study was published in the Journal of Medicinal Chemistry, a publication of the American Chemical Society.

Explore further: Discovery could reduce chemotherapy's side effects

Related Stories

Discovery could reduce chemotherapy's side effects

March 11, 2012
A team of researchers at Duke University has determined the structure of a key molecule that can carry chemotherapy and anti-viral drugs into cells, which could help to create more effective drugs with fewer effects to healthy ...

New ruthenium-based drugs show promise for killing cancer cells

June 11, 2012
A new study by University of Kentucky researchers shows how light and strained ruthenium-based drugs may be more effective at fighting cancer cells and less toxic to healthy cells than a similar and widely used drug.

Protein 'switches' could turn cancer cells into tiny chemotherapy factories

September 23, 2011
Johns Hopkins researchers have devised a protein "switch" that instructs cancer cells to produce their own anti-cancer medication.

Recommended for you

Lung cancer triggers pulmonary hypertension

November 17, 2017
Shortness of breath and respiratory distress often increase the suffering of advanced-stage lung cancer patients. These symptoms can be triggered by pulmonary hypertension, as scientists at the Max Planck Institute for Heart ...

Researchers discover an Achilles heel in a lethal leukemia

November 16, 2017
Researchers have discovered how a linkage between two proteins in acute myeloid leukemia enables cancer cells to resist chemotherapy and showed that disrupting the linkage could render the cells vulnerable to treatment. St. ...

Computer program finds new uses for old drugs

November 16, 2017
Researchers at the Case Comprehensive Cancer Center at Case Western Reserve University School of Medicine have developed a computer program to find new indications for old drugs. The computer program, called DrugPredict, ...

Pharmacoscopy improves therapy for relapsed blood cancer in a first clinical trial

November 16, 2017
Researchers at CeMM and the Medical University of Vienna presented a preliminary report in The Lancet Hematology on the clinical impact of an integrated ex vivo approach called pharmacoscopy. The procedures measure single-cell ...

Wider sampling of tumor tissues may guide drug choice, improve outcomes

November 15, 2017
A new study focused on describing genetic variations within a primary tumor, differences between the primary and a metastatic branch of that tumor, and additional diversity found in tumor DNA in the blood stream could help ...

A new strategy for prevention of liver cancer development

November 14, 2017
Primary liver cancer is now the second leading cause of cancer-related death worldwide, and its incidences and mortality are increasing rapidly in the United Stated. In late stages of the malignancy, there are no effective ...

1 comment

Adjust slider to filter visible comments by rank

Display comments: newest first

Smarrelli
not rated yet Aug 30, 2012
This sounds incredible. A couple of questions though..

I don't think I saw it mentioned in the article, but how would the drug be administered? Tablet, injection etc.

Secondly, where would this drug fit in the general approach to treating cancer? Would it be used in conjunction with chemo? i.e. taken after chemo to prevent the reparation of cancer cells, or could this be an alternative to chemo depending on the type, and progression of the cancer?

Please sign in to add a comment. Registration is free, and takes less than a minute. Read more

Click here to reset your password.
Sign in to get notified via email when new comments are made.